Public biotech 2000?the numbers

Lähteenmäki, Riku; Fletcher, Liz
May 2001
Nature Biotechnology;May2001, Vol. 19 Issue 5, p407
Academic Journal
Reports on the performance of biotechnology companies during the year 2000. Number of private biotechnology companies which became public companies; Statistics for total revenue, research and development spendings, profit and loss for the companies in the duration; Names of the top 10 biotechnology companies during the year; Details of mergers and acquisitions in the biotechnology field.


Related Articles

  • Public biotechnology 2004—the numbers. LÄhteenmÄki, Riku; Lawrence, Stacy // Nature Biotechnology;Jun2005, Vol. 23 Issue 6, p663 

    The article presents a discussion on the public biotechnology in the year 2004. In 2004, public biotechnology companies made gains in revenues and profits, but with stock markets lackluster and regulatory issues looming, future growth remains uncertain. Three hundred and nine biotechnology firms...

  • COMPANY SPOTLIGHT - Genentech, Inc.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p22 

    The article profiles Genentech Inc., a biotechnology company, which focuses on the discovery, development and marketing of biotherapeutics for serious medical conditions in the U.S. The company has accounted a net income of $931 million in the fourth quarter of 2007, an operating revenue which...

  • Biotech Earnings Show Positive Rebound During Second Quarter. Mirasol, Feliza // Chemical Market Reporter;07/24/2000, Vol. 258 Issue 4, p13 

    Focuses on the earnings of biotechnology companies in the second quarter of 2000. Companies that reported growth in the quarter; Reasons for their revenue growth.

  • Biotech industry tries to recover from 2-year lull. Brower, Vicki // JNCI: Journal of the National Cancer Institute;3/5/2003, Vol. 95 Issue 5, p348 

    Looks at the financial performance of the biotechnology industry in the U.S. Role of the corporate side of biotechnology firms in the downward turn of the industry; Advantage of biotechnology drugs over technology products in terms of long-term investment; Effect of cancer drug approval on...

  • The Widening Gap Between Major and Emerging Biotech Players. Van Arnum, Patricia // Chemical Market Reporter;6/16/2003, Vol. 263 Issue 24, pFR2 

    Examines the widening revenue gap between major and emerging biotechnology companies. Sales of leading products in emerging biotech sector; Revenue for leading therapeutic proteins; Factors affecting the performance of the industry.

  • Company Overview.  // Takara Holdings, Inc. SWOT Analysis;Nov2005, p4 

    The article presents information on Takara Holdings Inc. a Japanese holding company engaged in the alcohol, food and bio businesses. Information on the company's subsidiaries is provided. Revenue posted during the fiscal year ended March 2005 is revealed. Net profit during fiscal year 2005 is...

  • EXACTECH'S 2007 NET INCOME INCREASED 9% TO $8.5 MILLION.  // Biotech Financial Reports;Apr2008, Vol. 15 Issue 4, p2 

    No abstract available.

  • UNITED THERAPEUTICS HAS 1ST QTR 2010 REVENUES OF $128.9 MIL.  // Biotech Financial Reports;Jun2010, Vol. 17 Issue 6, p5 

    The article reports on the financial performance of Silver Spring, Maryland-based biotechnology firm United Therapeutics Corp. during the first quarter of 2010 that ended on March 31. It mentions that United Therapeutics' has a total revenue of 128.9 million dollars during the first quarter of...

  • Public biotech 2008—the numbers. Huggett, Brady; Hodgson, John; Lähteenmäki, Riku // Nature Biotechnology;Aug2009, Vol. 27 Issue 8, p710 

    This article discusses the results of a survey of public biotech companies conducted by the journal "Nature Biotechnology" in 2008. It highlights the study's confirmation of the financial challenges facing the biotechnology sector. It also indicates the sector's need for financing due to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics